$38.74 Million in Sales Expected for Codexis, Inc. (NASDAQ:CDXS) This Quarter

Brokerages forecast that Codexis, Inc. (NASDAQ:CDXSGet Rating) will report sales of $38.74 million for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Codexis’ earnings, with the highest sales estimate coming in at $42.30 million and the lowest estimate coming in at $35.30 million. Codexis reported sales of $25.45 million during the same quarter last year, which indicates a positive year-over-year growth rate of 52.2%. The business is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Codexis will report full year sales of $154.91 million for the current financial year, with estimates ranging from $153.10 million to $157.69 million. For the next year, analysts expect that the business will report sales of $173.54 million, with estimates ranging from $153.10 million to $188.42 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Codexis.

Codexis (NASDAQ:CDXSGet Rating) last released its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. Codexis had a negative return on equity of 12.56% and a negative net margin of 16.85%. The business had revenue of $35.34 million for the quarter, compared to the consensus estimate of $28.58 million. During the same quarter in the previous year, the company posted ($0.14) EPS. The company’s revenue was up 96.0% compared to the same quarter last year.

Several research firms have recently weighed in on CDXS. StockNews.com began coverage on Codexis in a research report on Thursday, March 31st. They set a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and set a $38.00 target price on shares of Codexis in a research report on Friday, February 25th. Zacks Investment Research downgraded Codexis from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. Cowen started coverage on Codexis in a research report on Wednesday, March 2nd. They issued a “buy” rating and a $39.00 price objective on the stock. Finally, TheStreet downgraded Codexis from a “c-” rating to a “d” rating in a research report on Thursday, February 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Codexis presently has an average rating of “Buy” and a consensus target price of $30.83.

In related news, Director Dennis P. Wolf sold 4,000 shares of the company’s stock in a transaction on Wednesday, March 23rd. The stock was sold at an average price of $20.49, for a total transaction of $81,960.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John J. Nicols sold 38,500 shares of the company’s stock in a transaction on Thursday, March 10th. The stock was sold at an average price of $18.93, for a total value of $728,805.00. The disclosure for this sale can be found here. Insiders sold a total of 81,000 shares of company stock valued at $1,207,700 over the last quarter. Company insiders own 7.50% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC raised its stake in Codexis by 25.6% in the first quarter. FMR LLC now owns 917,537 shares of the biotechnology company’s stock valued at $18,837,000 after buying an additional 187,000 shares during the last quarter. Advisor Group Holdings Inc. raised its stake in Codexis by 70.4% in the third quarter. Advisor Group Holdings Inc. now owns 3,814 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 1,576 shares during the last quarter. Principal Financial Group Inc. raised its stake in Codexis by 3.9% in the third quarter. Principal Financial Group Inc. now owns 25,255 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 955 shares during the last quarter. Barclays PLC raised its stake in Codexis by 153.3% in the third quarter. Barclays PLC now owns 55,782 shares of the biotechnology company’s stock valued at $1,297,000 after buying an additional 33,761 shares during the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in Codexis in the third quarter valued at about $216,000.

NASDAQ CDXS opened at $10.51 on Tuesday. The company has a market cap of $686.35 million, a P/E ratio of -31.85 and a beta of 1.96. The business’s 50 day moving average price is $15.99 and its 200-day moving average price is $22.92. Codexis has a fifty-two week low of $9.47 and a fifty-two week high of $42.01.

Codexis Company Profile (Get Rating)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Featured Stories

Get a free copy of the Zacks research report on Codexis (CDXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.